BRCA1 and neoplasm: Wang et al demonstrated that the limited response of BRCA1-deficient breast tumors to PARPi is mainly due to M2-like pro-tumor macrophages, which inhibits CD8+ T cells in the immune system and impedes PARPi-triggered tumor cell DNA damage as well.